BOVOGEN公司 BOVOGEN代理 BOVOGEN**代理 BOVOGEN中国代理
一个bobo生物制品
Bovogen Biologicals是一家私营公司在澳大利亚墨尔本，研究，制造和供应高纯度的动物蛋白质，酶和动物血清产品给全球制药，诊断和生命科学界。
使命声明
Bovogen Biologicals旨在成为全球**的生物精细化学品制造商，由牛副产品或相关原料生产。
我们的使命是确保我们的产品质量每次都符合并超出我们的规格。我们也以我们的能力超越客户对质量，产品交付和服务的期望而感到自豪。Bovogen Biologicals的文化将成为我们客户的行业合作伙伴，而不仅仅是供应商。
公司简介
Bovogen Biologicals由Rick Clements于2001年成立，旨在利用专有的热冲击工艺制造澳大利亚原产牛血清白蛋白（BSA）。
从那时起，Bovogen Biologicals已经扩大了不可思议地在呼唤不需要他们的全球客户的需求se，提供广泛的澳大利亚或新西兰来源纯化的动物蛋白质，包括牛免疫球蛋白，纤维蛋白原，胎儿蛋白，转铁蛋白，干血浆和血红蛋白和胎盘提取物。
支持本次博览会潜在增长Bovogen Biologicals的GMP制造工厂的规模已经增加了三倍，并增加了可用于co的工业容量冷冻干燥套件ntract制造和一个专用的无菌过滤设备e澳大利亚或新西兰起源胎牛血清（FBS），新生小牛血清（NBCS），成年牛血清（ABS）和其他动物血清如猪，羊和马进行处理。
Bovogen Biologicals在澳大利亚严格的GMP制造，确保其产品通过使用o符合*高质量标准澳大利亚或新西兰原产动物衍生的原料，从美国农业部和欧盟批准的设施收集。由澳大利亚或新西兰来源，经完整的动物追踪记录证实，Bovogen Biologicals生产的产品不存在co任何已知会感染其他地区牲畜的主要流行病，如疯牛病和口蹄疫的病例。
质量的这种保证在整个制药和生物技术行业得到广泛的认可e Bovogen Biologicals的产品用于从疫苗生产到兽医诊断的应用。BA在其研究和开发的基础上，Bovogen Biologicals仍然致力于通过公司与生物制药界合作制造，合作研究项目和行业合作伙伴关系的形成，期待着共同合作适应客户对动物衍生生物的需求。
咨询委员会
肯尼迪医生：MBBS，FACSP，FACSM，FASMF
David Kennedy博士是一名合格的医疗实习具有超过25年的肌肉骨骼医学经验和训练。他曾在斯坦福大学，梅奥诊所和多伦多大学工作。*近，他一直参与澳大利亚和亚太地区一些生物技术公司的开发和商业化。
肯尼迪博士是创世纪生物医药有限公司的创始董事，该公司是亚太区Codon AG组织工程总裁兼**执行官，也是CollTech澳大利亚有限公司的创始人，总监兼**运营官。他目前是生物技术开发有限公司总经理，澳大利亚生物科技园有限公司他也是新加坡菲利克斯资本投资有限公司的联合创始人兼董事sed资本投资公司。
他在北美，欧洲和亚洲生活和工作，结合他的医疗和科学专业知识与他的商业和营销技能。
Ted Stelmasiak博士：DVM博士，MACVSc
博士Stelmasiak 博士是Glutagen Pty Ltd的创始人兼**执行官，Glutagen Pty Ltd是一家专门研发Coeliacs疾病治疗的公司。Stelmasiak博士还是Anadis有限公司的创始董事和前研究总监。
他是兽医病理学家，拥有超过25年的经验，发表了超过60篇科学论文，提交了多项**，开发了多项商业上可行的生物制药产品。
Neil H. Goss博士：B.Sc.，B.Sc. （荣誉），博士
高斯博士是生物技术公司进一步选择有限公司执行董事公司和Lynx生物制药有限公司总监，Lynx Biopharmaceutical Pty。Ltd.是一家专门从事疫苗和血浆产品销售和营销的公司。
他在血浆骨折中有超过25年的经验国家和生物技术行业，曾担任CSL生物等级研究与开发总监。戈斯博士在科学，技术和管理领域和公司方面拥有丰富的经验广泛地归结于national和international医疗保健社区。
有关我们产品的更多信息，请参见：
纯化蛋白
动物血清产品
酶
凝血蛋白
胎盘提取物
大批量干动物血液制品
动物腺体和器官
about Bovogen Biologicals
Bovogen Biologicals is a privately-owned company based in Melbourne, Australia, that researches, manufactures and supplies highly purified animal proteins, enzymes and animal serum products to the global pharmaceutical, diagnostics and life science communities.
Mission Statement
Bovogen Biologicals aims to be a leading global manufacturer of biological fine chemicals derived from bovine by-products or related raw materials.
Our mission is to guarantee that the quality of our products will meet and exceed our specifications each and every time. We also take pride in our ability to surpass customer expectations for quality, product delivery and service. Bovogen Biologicals' culture is to become an industry partner with our customers, not just a supplier.
Company Overview
Bovogen Biologicals was established in 2001 by Rick Clements for the purpose of manufacturing Australian origin Bovine Serum Albumin (BSA) utilising a proprietary Heat Shock Process.
Since that time, Bovogen Biologicals has expanded considerably in response to the needs of their global customer base, to offer an extensive range of Australian or New Zealand origin purified animal proteins which include Bovine Immunoglobulin, Fibrinogen, Fetuin, Transferrin, Dried Plasma and Haemoglobin and Placenta Extracts.
In support of this exponential growth Bovogen Biologicals' GMP manufacturing facility has more than tripled in size with the addition of an industrial capacity freeze drying suite which is available for contract manufacturing and a purpose built sterile filtration facility where Australian or New Zealand origin Foetal Bovine Serum, (FBS), Newborn Calf Serum (NBCS), Adult Bovine Serum (ABS) and other animal sera such as porcine, ovine and equine, are processed.
Manufactured in Australia under strict GMP, Bovogen Biologicals ensures that their products meet the highest quality standards by using only Australian or New Zealand origin animal derived raw materials, collected from USDA & EU approved facilities. Being of Australian or New Zealand origin, as verified by the availability of complete animal traceability records, products manufactured by Bovogen Biologicals are free of the risk of contamination from any major epidemic diseases, such as BSE & Foot and Mouth Disease which are known to infect livestock in other regions.
This assurance of quality is recognized widely around the world throughout the pharmaceutical and biotechnology industries, where Bovogen Biologicals' products are used in applications from vaccine manufacturing to veterinary diagnostics. based on its foundation of research and development, Bovogen Biologicals remains committed to working with the biopharmaceutical community through contract manufacturing, collaborative research projects and the formation of industry partnerships and looks forward to continuing to meet its customers' needs for animal derived biologicals.
Advisory Board
Dr David Kennedy: MBBS, FACSP, FACSM, FASMF
Dr. David Kennedy is a qualified medical practitioner with over 25 years experience and training in musculo-skeletal medicine. He has worked at Stanford University, Mayo Clinic and the University of Toronto. More recently he has been involved in the development and commercialization of a number of Biotechnology companies in Australia and the Asia-Pacific region.
Dr. Kennedy was a founding director of Genesis Biomedical Ltd, President and CEO of Codon AG Tissue Engineering in the Asia Pacific region and a founder, director and COO of CollTech Australia Ltd. He is currently the General Manager of Biotechnology Development Pty Ltd and Australian Biotechnology Park Pty Ltd. He is also the co-founder and director of Felix Capital Investments Limited, a Singapore based capital investment company.
He has lived and worked in North America, Europe and Asia combining his medical and scientific expertise with his commercial and marketing skills.
Dr. Ted Stelmasiak: DVM, PhD, MACVSc
Dr. Stelmasiak is the founder and Chief Executive Officer of Glutagen Pty Ltd, a company specializing in the development of treatments for Coeliacs disease. Dr. Stelmasiak was also a founding Director and former Director of Research of Anadis Limited.
He is veterinary pathologist with over 25 years experience who has published over 60 scientific papers, filed several patents and developed a number of commercially viable biopharmaceutical products.
Dr Neil H. Goss: B.Sc., B.Sc. (Hons), Ph.D.
Dr Goss is Executive Director of Further Options Pty. Ltd., a biotechnology consulting company, and Director of Lynx Biopharmaceutical Pty. Ltd., a company specializing in the sales and marketing of vaccines and plasma products.
He has over 25 years of experience in the plasma fractionation and biotechnology industries and was formerly Director of Research and Development at CSL Bioplasma. Dr Goss has broad experience in scientific, technical and management areas and consults widely to the national and international healthcare community.
For more information on our products see:
Purified Proteins
Animal Serum Products
Enzymes
Clotting Proteins
Placenta Extracts
Bulk Dried Animal Blood Products
Animal Glands and Organs
